Provided By Globe Newswire
Last update: Oct 19, 2022
Merger brings U.S. management and presence, cash to develop compelling late-stage asset
Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors
Read more at globenewswire.com